Lp(a) as therapeutic target - now and in the future10' education - Oct. 28, 2021 - Prof. Erik Stroes, MD, PhD - Amsterdam, The Netherlands - Online CME
Click here to watch this as part of CME accredited course
Video navigation menu
- How much Lp(a) lowering is required? 00:40
- Effects of currently available lipid-lowering treatments on Lp(a) levels 01:50
- RNA-based therapies and Lp(a) 05:09
- What patients could potentially benefit from potent Lp(a) lowering? 07:44
This lecture by prof. Erik Stroes was part of an accredited symposium "Lp(a): from CV risk marker to therapeutic target" held during the virtual ESC Congress 2021.
Prof. Erik Stroes, MD, PhD is professor of Vascular Medicine at Amsterdam University Medical Centers in Amsterdam, The Netherlands.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by unrestricted educational grants received from Sanofi and Novartis.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: